Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

E. E. A. P. Mulder, K. de Joode, S. Litiere, A. J. ten Tije, K. P. M. Suijkerbuijk, M. J. Boers-Sonderen, G. A. P. Hospers, J. W. B. de Groot, A. J. M. van den Eertwegh, M. J. B. Aarts, D. Piersma, R. S. van Rijn, E. Kapiteijn, G. Vreugdenhil, F. W. P. J. van den Berkmortel, E. Oomen-de Hoop, M. G. Franken, B. Ryll, P. Rutkowski, S. SleijferJ. B. A. G. Haanen, A. A. M. van der Veldt*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number323
Number of pages9
JournalBMC Cancer
Volume21
Issue number1
DOIs
Publication statusPublished - 25 Mar 2021

Keywords

  • Melanoma
  • Advanced and metastatic
  • PD-1 blockade
  • Response (complete or partial)
  • Health-related quality of life

Cite this